Navigation Links
Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
Date:6/15/2012

AMSTERDAM, June 15, 2012 /PRNewswire/ --

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant. Patients received blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle, for up to five treatment cycles. Patients received a continuous intravenous infusion of blinatumomab at an initial dose of five or 15 micrograms/m2 per day, escalating to 30 micrograms for the remainder of the treatment. The primary endpoint of the study was the rate of complete remission (CR) and complete remission with partial hematologic recovery (CRh*). Secondary endpoints included molecular response rate, duration of response and overall survival. All 36 patients were evaluable for efficacy and safety.

Twenty-six of the 36 patients (72%) treated with blinatumomab across all of the tested doses and schedules achieved a CR/CRh*. All but two patients achieved a molecular response, meaning there was no evidence of leukemic cells by polymerase chain reaction. The most common adverse events were pyrexia, headache and tremor. Medically important safety events were reversible cytokine release syndrome and CNS adverse events.

At the time of the analysis, median survival was 9.0 (8.2, 15.8) months with a median follow-up period of 10.7 months. The median duration of response in the 26 patients who responded to treatment was 8.9 months.

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17th Congress of EHA is taking place in Amsterdam. Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases (in the production) of blood and their treatments. The latest data on research and developments within the wide spectrum of hematology are presented.

 


'/>"/>
SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
2. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
4. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
5. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
6. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
7. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
8. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
9. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
10. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
11. GeneLink Reports First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci has been manufacturing ... laboratories all over the globe. Their cute firefly logo has been spreading to ... FireflySci makes spectrophotometer calibration standards that never require recalibration. These revolutionary standards ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board ... BIO 2016 in San Francisco. Located at booth number 7301, representatives from the ... questions and discuss the Thai biotechnology and life sciences sector. , Deputy ...
(Date:5/25/2016)... ... 2016 , ... Founder of the Fitzmaurice Hand Institute in ... of the hand by the National Board of Physicians and Surgeons, as of ... in his pursuit of providing the most comprehensive, effective treatment for his patients, ...
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the variety ... that could lead to one good one. Surviving Mesothelioma has just posted an article ... team evaluated 98 mesothelioma patients who got a second kind of drug ...
Breaking Biology Technology:
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
Breaking Biology News(10 mins):